Table 2. MITRA-FR and COAPT trials.
| Features | MITRA-FR trial | COAPT trial |
|---|---|---|
| Patients’ characteristics | ||
| Age (years) | 70 | 72 |
| Male (sex) | 74 | 64 |
| LVEF | 33.1 | 31.3 |
| EROA (mm2) | 31 | 40.5 |
| LVESD (mm) | – | 53 |
| LVEDV (mL/m2) | 135 | 101 |
| RV systolic pressure (mmHg) | 54 | 44.3 |
| NYHA class III–IV | 69 | 60 |
| Diabetes mellitus | 29.3 | 37.3 |
| GFR (mL/min/1.73 m2) | 49.6 | 49.3 |
| Hypertension | – | 80.4 |
| Medical treatment | ||
| Beta-blockers | 89.5 | 90.3 |
| ACEI or ARB or ARNI | 84.7 | 67.1 |
| MRA | 54.8 | 50.1 |
| Diuretics | 98.6 | 89.1 |
| Procedural outcomes | ||
| Procedural success | 95.8 | 98 |
| Rate of 1 vs. >1 MitraClip | 46 | 36 |
| No MitraClip implantation | 4.2 | 5 |
| Acute MR 3+ or 4+ | 9 | 5 |
| Tamponade | 1.4 | 3 |
Patients’ characteristics and procedural outcomes. Values are % or mean. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitor; EROA, effective regurgitant orifice area; GFR, glomerular filtration rate; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; RV, right ventricular.